Literature DB >> 534216

[The treatment of brucellosis using rifampicine (author's transl)].

A Bertrand, J Roux, F Janbon, J Jourdan, O Jonquet.   

Abstract

The authors discuss the present value of rifampicin in the treatment of human brucellosis on the basis of: 1) a bacteriological study of 42 strains of Brucella spp. (MIC's of rifampicin, tetracyclin, doxycyclin, minocyclin and streptomycin; results of doxycyclin-rifampicin and doxycyclin-streptomycin combinations), and 2) a clinical study of 38 cases of brucellosis treated with rifampicin, including 25 acute septicemias and 13 osteo-arthritis. Satisfactory results were observed in 92% of the cases with rifampicin alone, but one cannot state that the benefits are significant.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 534216

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN： 0301-1518


  7 in total

1.  Possible implications of doxycycline-rifampin interaction for treatment of brucellosis.

Authors:  J D Colmenero; L C Fernández-Gallardo; J A Agúndez; J Sedeño; J Benítez; E Valverde
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

2.  Multicenter prospective study of treatment of Brucella melitensis brucellosis with doxycycline for 6 weeks plus streptomycin for 2 weeks.

Authors:  J M Cisneros; P Viciana; J Colmenero; J Pachón; C Martinez; A Alarcón
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 3.  Recognition and optimum treatment of brucellosis.

Authors:  J Solera; E Martínez-Alfaro; A Espinosa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

4.  Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.

Authors:  J Ariza; J Bosch; F Gudiol; J Liñares; P F Viladrich; R Martín
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

5.  Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.

Authors:  J Solera; M Rodríguez-Zapata; P Geijo; J Largo; J Paulino; L Sáez; E Martínez-Alfaro; L Sánchez; M A Sepulveda; M D Ruiz-Ribó
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

6.  Neonatal brucellosis.

Authors:  M M Lubani; K I Dudin; D C Sharda; N M Abu Sinna; T Al-Shab; A A Al-Refe'ai; S M Labani; A Nasrallah
Journal:  Eur J Pediatr       Date:  1988-06       Impact factor: 3.183

7.  Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis.

Authors:  J Ariza; F Gudiol; R Pallarés; G Rufí; P Fernández-Viladrich
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.